Logo

GLUE

Monte Rosa Therapeutics, Inc.

GLUE

Monte Rosa Therapeutics, Inc. • NASDAQ
$16.17 ▲ 1.13% (+0.18)
Market Cap $1.05 B
52w High $16.66
52w Low $3.50
Dividend Yield 0%
P/E 50.53
Volume 417.04K
Outstanding Shares 65.12M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $12.768M ▼ $43.648M ▲ $-27.081M ▼ -212.101% ▼ $-0.33 ▼ $-28.163M ▼
Q2-2025 $23.194M ▼ $38.748M ▼ $-12.295M ▼ -53.009% ▼ $-0.15 ▼ $-13.429M ▼
Q1-2025 $84.929M ▲ $40.893M ▼ $46.885M ▲ 55.205% ▲ $0.57 ▲ $46.084M ▲
Q4-2024 $60.647M ▲ $47.643M ▲ $13.437M ▲ 22.156% ▲ $0.22 ▲ $15.065M ▲
Q3-2024 $9.216M $35.743M $-23.859M -258.887% $-0.29 $-24.424M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $391.258M ▲ $459.841M ▲ $214.004M ▲ $245.837M ▼
Q2-2025 $290.594M ▼ $359.586M ▼ $91.506M ▼ $268.08M ▼
Q1-2025 $326.074M ▼ $393.199M ▼ $118.039M ▼ $275.16M ▲
Q4-2024 $372.149M ▲ $438.732M ▲ $215.796M ▲ $222.936M ▲
Q3-2024 $242.186M $315.08M $109.623M $205.457M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-27.081M ▼ $100.428M ▲ $38.138M ▲ $348K ▼ $138.914M ▲ $99.777M ▲
Q2-2025 $-12.295M ▼ $-34.72M ▲ $25.324M ▲ $365K ▲ $-9.031M ▲ $-36.415M ▲
Q1-2025 $46.885M ▲ $-45.492M ▼ $-100.229M ▼ $14K ▼ $-145.724M ▼ $-47.079M ▼
Q4-2024 $13.437M ▲ $128.922M ▲ $-30.896M ▼ $608K ▲ $98.634M ▲ $128.739M ▲
Q3-2024 $-23.859M $-20.994M $37.749M $15K $16.77M $-21.393M

Five-Year Company Overview

Income Statement

Income Statement Monte Rosa is still very much a research-stage biotech with essentially no product sales yet. Reported revenue appears to be driven mainly by collaboration and licensing activity, not by marketed drugs. Operating costs are substantial as the company invests heavily in research, clinical trials, and platform development, which leads to ongoing net losses. The encouraging sign is that losses have narrowed recently, suggesting better cost control and the benefit of partnership income, but the business remains far from self-funding through its own products.

Balance Sheet

Balance Sheet The balance sheet is dominated by cash and short-term investments, which is typical for an early-stage biotech. Debt levels are relatively modest compared with the cash position, and shareholders’ equity has moved firmly into positive territory after being negative several years ago. This indicates the company has been able to strengthen its financial foundation, likely through equity raises and upfront payments from partners. However, because the asset base is mostly cash rather than tangible operating assets, the company’s strength depends heavily on how long that cash can support its research plans.

Cash Flow

Cash Flow Historically, Monte Rosa has used cash in its operations, reflecting the cost of R&D and the absence of product sales. The most recent year shows a notable improvement, with operating and free cash flow turning positive, likely helped by large upfront payments from pharmaceutical partners and disciplined spending. This is a positive shift, but it is important to recognize that the cash inflows are not yet coming from recurring product revenue; they depend on milestones, deals, and financing. Future cash flow will be highly sensitive to the timing of clinical results, partnership milestones, and any new collaborations or capital raises.

Competitive Edge

Competitive Edge Monte Rosa occupies a strong niche in the emerging field of molecular glue degraders, a next-generation approach to targeted therapies. Its proprietary QuEEN platform, which uses advanced AI and machine learning, is a key differentiator that aims to unlock disease targets previously considered out of reach. High-profile partnerships with Novartis and Roche provide external validation, access to additional resources, and a broader reach across multiple disease areas. At the same time, the broader protein degradation space is attracting intense interest, including from large pharmaceutical companies, so Monte Rosa must continue to move quickly, generate compelling data, and defend its intellectual property to maintain its edge.

Innovation and R&D

Innovation and R&D Innovation is clearly the core of Monte Rosa’s strategy. The QuEEN platform is designed to systematically discover and optimize molecular glue degraders, giving the company a technology engine rather than a one-off project. The pipeline spans autoimmune diseases, oncology, and inflammatory conditions, with several named programs already in or near the clinic and additional earlier-stage efforts behind them. R&D spending is heavy, as expected, and the company’s long-term value will depend on converting this scientific ambition into clear clinical proof, regulatory progress, and eventually commercial products. There is substantial upside potential if the platform keeps producing successful candidates, but also high risk if key trials disappoint.

Summary

Monte Rosa Therapeutics is a classic high-risk, high-innovation biotech story: it has cutting-edge science, strong academic and industry validation, and meaningful pharma partnerships, but it is still pre-commercial and loss-making. The financial profile shows a company that has bolstered its cash resources and reduced its burn rate with help from collaborations, giving it a multi-year runway to pursue its programs. The strategic position in molecular glue degraders, backed by an AI-driven discovery engine, offers a differentiated path in an increasingly competitive field. Ultimately, the company’s trajectory will hinge on clinical data over the next few years, the continued productivity of its platform, and its ability to maintain and deepen key partnerships. This combination creates meaningful upside potential alongside significant execution and scientific risk, typical of early-stage biotech firms.

NEWS

November 19, 2025 · 9:00 AM UTC

BETTY NAMED CREATIVE AGENCY OF RECORD FOR GORILLA GLUE

Read more

November 8, 2025 · 11:30 AM UTC

Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases

Read more

November 6, 2025 · 7:00 AM UTC

Monte Rosa Therapeutics Announces Third Quarter 2025 Financial Results and Business Updates

Read more

November 3, 2025 · 7:00 AM UTC

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

Read more

October 24, 2025 · 7:00 AM UTC

Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2025 on the Potential of MRT-6160, a VAV1-directed Molecular Glue Degrader, to Treat Immune-mediated Diseases

Read more